Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin sustained-release tablet (III) for newly diagnosed type 2 diabetes
ChiCTR2400092286Phase 4Not yet recruiting
- Sponsor
- Peking University First Hospital Department of Endocrinology
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of metformin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Peking University First Hospital Department of Endocrinology. Primary endpoint: Change in hemoglobin A1c from baseline to 24 weeks. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2400092286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092286.